Home >Current Issue
Volume: 9, Issue: 7, July, 2019
Impact of hospital pharmacist-led home medication review program for people with schizophrenia: A prospective study from MalaysiaAuthor Affiliations
This study was to evaluate the impact of hospital pharmacist-led home medication review (HMR) program on medication adherence, knowledge toward antipsychotic drugs, and quality of life among people with schizophrenia. This was a prospective longitudinal study conducted from October 2012 to December 2013. This study involved 133 people with schizophrenia under the care of the home care team in Hospital Bahagia Ulu Kinta Hospital, Malaysia. Upon attaining written informed consent, subjects were home visited after 1, 3, and 6 months by the pharmacist to perform a comprehensive medication review. Friedman analysis of variance test was used to compare the differences of the patients’ medication adherence, knowledge of antipsychotic treatment, and quality of life at baseline and each follow-up visit. Subjects had a significant improvement on medication adherence as shown by the mean medication adherence rating scale scores (baseline: 8.42 ± 1.40 vs. sixth month: 9.47 ± 1.02; p < 0.001) and mean pill count percentage (baseline: 56.68% ± 39.43% vs. sixth month: 90.37% ± 15.19%; p < 0.001). Subjects’ mean knowledge score on antipsychotics were improved significantly with the HMR program (baseline: 5.56 ± 1.51 vs. sixth month: 7.65 ± 0.60; p < 0.001). Regarding the subject’s quality of life, the “social” and the “family” components of the Sheehan disability scale demonstrated significant improvement (p < 0.001). However, the improvement of the “work” component and overall quality of life were not statistically significant. In conclusion, pharmacist-led HMR program has a positive impact on medication adherence, knowledge of antipsychotics, and quality of life on “social” and “family” components among people with schizophrenia.
Copyright: The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Aziz SA. The first report of the National Mental Health Registry on schizophrenia. National Mental Health Registry, Department of Psychiatry and Mental Health, Hospital Kuala Lumpur, Kuala Lumpur, 2007 [Online]. Available via http://www.crc.gov.my/wp-content/uploads/ documents/report/NMHR1stReport.pdf (Accessed 20 January 2015).
Barker A, Barlis P, Berlowitz D, Page K, Jackson B, Lim WK. Pharmacist directed home medication reviews in patients with chronic heart failure: a randomised clinical trial. Int J Cardiol, 2012; 159(2):139-43. https://doi.org/10.1016/j.ijcard.2011.02.034
Barkhof E, Meijer CJ, De Sonneville LM, Linszen DH, De Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-a review of the past decade. Eur Psychiatry, 2012; 27(1):9-18. https://doi.org/10.1016/j.eurpsy.2011.02.005
Begley S, Livingstone C, Hodges N, Williamson V. Impact of domiciliary pharmacy visits on medication management in an elderly population. Int J Pharm Pract, 1997; 5(3):111-21. https://doi.org/10.1111/j.2042-7174.1997.tb00895.x
Bland JM, Butland BK, Peacock JL, Poloniecki J, Reid F, Sedgwick P. Statistic guide for research grant applicants. St George's Hospital Medical School, London, UK, 2012 [Online]. Available via http://www-users.york.ac.uk/~mb55/guide/guide14.pdf (Accessed 20 January 2015).
Chan S, Yu IuW. Quality of life of clients with schizophrenia. J Adv Nurs, 2004; 45(1):72-83. https://doi.org/10.1046/j.1365-2648.2003.02863.x
Council of Europe CoM. Resolution ResAP (2001) 2 concerning the pharmacist's role in the framework of health security. Council of Europe, Strasbourg, 2001 [Online]. Available via https://wcd.coe.int/ViewDoc. jsp?id=193721&Site=CM (Accessed 20 January 2015).
Dahlan R, Midin M, Shah SA, Nik Jaafar NR, Abdul Rahman FN, Baharudin A, Das S, Sidi H. Functional remission and employment among patients with schizophrenia in Malaysia. Compr Psychiatry, 2014; 55(Suppl 1):S46-51. https://doi.org/10.1016/j.comppsych.2013.03.007
Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, Mesters P. Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. J Clin Psychiatry, 2001; 62(Suppl 22):34-7.
Family Health Department Division. Garispanduan pelaksanaan perkhidmatan pemulihan psikososial bagi pesakit mental di penjagaan kesihatan primer. Ministry of Health Malaysia, Kuala Lumpur, Malaysia, 2001.
Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull, 1997; 23(4):637-51. https://doi.org/10.1093/schbul/23.4.637
Finley PR, Rens HR, Pont JT, Gess SL, Louie C, Bull SA, Bero LA. Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health Syst Pharm, 2002; 59(16):1518-26. https://doi.org/10.1093/ajhp/59.16.1518
Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother, 1998; 32(7-8):749-54.
Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence (review). Cochr Datab Syst Rev, 2008; 2:CD000011; doi: 10.1002/14651858.CD000011.pub3 https://doi.org/10.1002/14651858.CD000011.pub3
Holland R, Desborough J, Goodyer L, Hall S, Wright D, Loke YK. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br J Clin Pharmacol, 2008; 65(3):303-16. https://doi.org/10.1111/j.1365-2125.2007.03071.x
Holland R, Lenaghan E, Harvey I, Smith R, Shepstone L, Lipp A, Christou M, Evans D, Hand C. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ, 2005; 330(7486):293. https://doi.org/10.1136/bmj.38338.674583.AE
Hussainy SY, Box M, Scholes S. Piloting the role of a pharmacist in a community palliative care multidisciplinary team: an Australian experience. BMC Palliat Care, 2011;10:16l doi: 10.1186/1472-684X-10-16 https://doi.org/10.1186/1472-684X-10-16
Keefe RS, Harvey PD. Cognitive impairment in Schizophrenia. Handb Exp Pharmacol, 2012; 213:11-37. https://doi.org/10.1007/978-3-642-25758-2_2
Lenaghan E, Holland R, Brooks A. Home-based medication review in a high risk elderly population in primary care-the POLYMED randomised controlled trial. Age Ageing, 2007; 36(3):292-7. https://doi.org/10.1093/ageing/afm036
Lowe CJ, Raynor DK, Purvis J, Farrin A, Hudson J. Effects of a medicine review and education programme for older people in general practice. Br J Clin Pharmacol, 2000; 50(2):172-5. https://doi.org/10.1046/j.1365-2125.2000.00247.x
Ministry of Health Malaysia. Clinical practice guidelines: management of schizophrenia in adults. Ministry of Health Malaysia, Putrajaya, 2009 [Online]. Available via http://www.acadmed.org.my/index. cfm?&menuid=67 (Accessed 10 August 2015).
Mustapa MD, Wong YC, Thiruvanackan K. Improving patients' medication compliance and treatment outcome through Home Medication Review (HMR) conducted by pharmacists at primary health clinics in the state of Selangor. Paper presented at 5th National Pharmacy R&D Conference, Hospital Putrajaya, Putrajaya, Malaysia, July 28-30, 2008.
Naunton M, Peterson GM. Evaluation of home-based follow-up of high-risk elderly patients discharged from hospital. J Pharm Pract Res, 2003; 33(3):176-82. https://doi.org/10.1002/jppr2003333176
Okuno J, Yanagi H, Tomura S, Oka M, Hara S, Hirano C, Tsuchiya S. Compliance and medicartion knowledge among elderly Japanese home-care recipients. Eur J Clin Pharmacol, 1999; 55(2):145-9. https://doi.org/10.1007/s002280050609
Raynor DK, Nicolson M, Nunney J, Petty D, Vail A, Davies L. The development and evaluation of an extended adherence support programme by community pharmacists for elderly patients at home. Int J Pharm Pract, 2000; 8(3):157-64. https://doi.org/10.1111/j.2042-7174.2000.tb01001.x
Shaw H, Mackie CA, Sharkie I. Evaluation of effect of pharmacy discharge planning on medication problems experienced by discharged acute admission mental health patients. Int J Pharm Pract, 2000; 8(2):144- 53. https://doi.org/10.1111/j.2042-7174.2000.tb00999.x
Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol, 1996; 11(Suppl 3):89-95. https://doi.org/10.1097/00004850-199606003-00015
Sorensen L, Stokes JA, Purdie DM, Woodward M, Elliott R, Roberts MS. Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol, 2004; 58(6):648-64. https://doi.org/10.1111/j.1365-2125.2004.02220.x
Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res, 2000; 42(3):241-7. https://doi.org/10.1016/S0920-9964(99)00130-9
Weiden PJ, Dixon L, Frances A. Neuroleptic noncompliance in schizophrenia. In: Tamminga CA, Schulz SC (eds.). Schizophrenia research. Raven Press, New York, pp. 285-96, 1991.
World Health Organization. The role of the pharmacist in the health care system. World Health Organization, Geneva, Switzertland, 1994 [Online]. Available via http://apps.who.int/medicinedocs/pdf/h2995e/ h2995e.pdf (Accessed 20 January 2015).
World Health Organization. Improving access and use of psychotropic medicines. World Health Organization, Geneva, Switzerland, 2005 [Online]. Available via http://www.who.int/mental_health/policy/ services/10_improving%20access_WEB_07.pdf?ua=1 (Accessed 20 January 2015).
Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Quality of life of Chinese schizophrenia outpatients in Hong Kong: relationship to sociodemographic factors and symptomatology. Aust N Z J Psychiatry, 2007; 41(5):442-9. https://doi.org/10.1080/00048670701261228
Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law, 1986; 14(2):105-22.